Loading clinical trials...
Loading clinical trials...
Study Assessing 20 mg/kg Dose of the Recombinant Human Monoclonal Antibody Against P-selectin in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
This randomized double-blind, placebo-controlled study will evaluate the efficacy and safety of RO4905417 in the prevention of saphenous vein graft disease in patients undergoing elective or urgent coronary artery bypass (CABG) surgery. Patients will be randomized to receive either RO4905417 20 mg/kg by intravenous infusion or placebo every 4 weeks for 32 weeks.
Age
18 - 85 years
Sex
ALL
Healthy Volunteers
No
Huntsville, Alabama, United States
Tucson, Arizona, United States
Los Angeles, California, United States
Los Angeles, California, United States
Atlantis, Florida, United States
Jacksonville, Florida, United States
Kissimmee, Florida, United States
Macon, Georgia, United States
Springfield, Illinois, United States
Springfield, Illinois, United States
Start Date
December 1, 2010
Primary Completion Date
May 1, 2013
Completion Date
May 1, 2013
Last Updated
November 2, 2016
384
ACTUAL participants
Placebo
DRUG
RO4905417
DRUG
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions